MESOBLAST LTD
MESO · XNASCIK 1345099fmd_0Y9J49S3Q5KRQBFKE0RZKCWTB7Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jul 01, 2015 to Jun 30, 2026, 31 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 2 | 17 | 17 | 32 | 7 | 10 | 8 | 6 | 17 | 120 |
| Cost of revenue | – | – | – | – | – | – | 0 | 0 | 5 | 17 |
| Gross profit | – | – | – | – | – | – | 8 | 6 | 12 | 104 |
| Research and development | 59 | 66 | 60 | 56 | 53 | 33 | 53 | 40 | 35 | 98 |
| Selling, general and administrative | – | – | – | – | – | – | 27 | 25 | 39 | 57 |
| Interest expense | – | 2 | 12 | 14 | 11 | 17 | 20 | 23 | 23 | 24 |
| Income before taxes | (90) | (66) | (99) | (87) | (100) | (92) | (82) | (88) | (102) | (57) |
| Income tax expense | (13) | (31) | (9) | (9) | (1) | (0) | (0) | (0) | 0 | 1 |
| Net income from continuing operations | (77) | (35) | (90) | (78) | (99) | (91) | (82) | (88) | (102) | (58) |
| Net income | (77) | (35) | (90) | (78) | (99) | (91) | (82) | (88) | (102) | (58) |